Zobrazeno 1 - 10 of 20 pro vyhledávání: '"J. H. FETTING"'
1
Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology
Autor: J C Weeks, R J Winn, A B Bredt, J H Fetting, Charles L. Bennett, Thomas J. Smith, M R Somerfield, B E Hillner, J Feinglass
Publikováno v: Journal of Clinical Oncology. 14:2511-2520
PURPOSE Dissemination of use of the hematopoietic colony-stimulating factors (CSFs) is unprecedented in oncology, with almost all physicians having experience with granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimula
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c8c270eedaf092a47f4ca21db2765a5
https://doi.org/10.1200/jco.1996.14.9.2511
Zobrazit plný text záznamu
2
Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG)
Autor: D L, Fairclough, J H, Fetting, D, Cella, W, Wonson, C M, Moinpour
Publikováno v: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 8(8)
The objective was to compare health related quality of life (QOL) in hormone receptor negative, node-positive breast cancer patients receiving adjuvant chemotherapy to determine whether a more intensive chemotherapy regimen has an adverse effect upon
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b407f167eff9c7db7a0e2c71757200af
https://pubmed.ncbi.nlm.nih.gov/10855346
Zobrazit plný text záznamu
3
Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma
Autor: B, Mikhak, M, Zahurak, M D, Abeloff, J H, Fetting, N E, Davidson, R C, Donehower, W, Waterfield, M J, Kennedy
Publikováno v: Cancer. 85(4)
A Phase II study was performed evaluating the disease free and overall survival rates associated with a dose-intensive, 16-week, doxorubicin-based adjuvant chemotherapy regimen in women with breast carcinoma andor = 10 involved axillary lymph nodes.E
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7eeecf24f2611c0f4fa6110ed49609fc
https://pubmed.ncbi.nlm.nih.gov/10091768
Zobrazit plný text záznamu
4
Phase II trial of menogaril as initial chemotherapy for metastatic breast cancer
Autor: M J, Kennedy, R C, Donehower, L B, Grochow, D S, Ettinger, J H, Fetting, M D, Abeloff
Publikováno v: Investigational new drugs. 8(3)
Eighteen women with metastatic breast cancer previously untreated with chemotherapy were entered on a phase II trial of intravenous menogaril, a new anthracycline derivative. Treatment was given at 140 mg/m2 on days 1 and 8 of each 28 day cycle. The
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d9d357db6b11595ec26ae77d9cc35410
https://pubmed.ncbi.nlm.nih.gov/2148742
Zobrazit plný text záznamu
5
Weight gain in patients with breast cancer receiving adjuvant treatment as a function of restraint, disinhibition, and hunger
Autor: D, DeGeorge, J J, Gray, J H, Fetting, B J, Rolls
Publikováno v: Oncology nursing forum. 17
Little is known about how/why women who receive adjuvant chemotherapy treatment, hormone therapy, or radiation for nonmetastatic breast cancer gain weight. This study's purpose was to use the restraint-disinhibition model to understand susceptibility
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1e5c561a099297c0958dcc57bc1160b0
https://pubmed.ncbi.nlm.nih.gov/2342980
Zobrazit plný text záznamu
8
Tastes associated with parenteral chemotherapy for breast cancer
Autor: J H, Fetting, P M, Wilcox, V R, Sheidler, J P, Enterline, R C, Donehower, L B, Grochow
Publikováno v: Cancer treatment reports. 69(11)
We employed a structured interview to retrospectively study tastes and vomiting associated with the parenteral components of cyclophosphamide, methotrexate, and 5-FU in 45 patients with stage II-IV breast cancer. Sixteen patients (36%) reported taste
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::685fd7887311b2711a580a06b3e39d4e
https://pubmed.ncbi.nlm.nih.gov/3841501
Zobrazit plný text záznamu
9
Anticipatory nausea and vomiting: does it remain a significant clinical problem?
Autor: M E, Stefanek, V R, Sheidler, J H, Fetting
Publikováno v: Cancer. 62(12)
A study performed 5 years ago in our clinic revealed a prevalence rate of 31% for anticipatory symptoms. This finding is consistent with other investigations. It was hypothesized that more effective management of postchemotherapy nausea and vomiting
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::935e20f2bb32fd218da76ae89702f03b
https://pubmed.ncbi.nlm.nih.gov/3191468
Zobrazit plný text záznamu
10
Anticipatory nausea and vomiting in an ambulatory medical oncology population
Autor: J H, Fetting, P M, Wilcox, B A, Iwata, E L, Criswell, L S, Bosmajian, V R, Sheidler
Publikováno v: Cancer treatment reports. 67(12)
We studied the prevalence of anticipatory nausea (AN) and anticipatory nausea and vomiting (ANV) in an ambulatory medical oncology population by self-report questionnaire over 7 weeks. Thirty-eight of 123 (31%) patients receiving parenteral chemother
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0555e7c802bab4070891eefe54b82d6b
https://pubmed.ncbi.nlm.nih.gov/6652626
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje